Intraocular implants and methods and kits therefor

Information

  • Patent Grant
  • 11865041
  • Patent Number
    11,865,041
  • Date Filed
    Tuesday, July 30, 2019
    4 years ago
  • Date Issued
    Tuesday, January 9, 2024
    4 months ago
Abstract
Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and maintains the patency of the canal without substantially interfering with transmural fluid flow across the canal. The devices utilize the natural drainage process of the eye and can be implanted with minimal trauma to the eye. Kits include a support and an introducer for implanting the support within Schlemm's canal. Methods include implanting a support within Schlemm's canal, wherein the support is capable of maintaining the patency of the canal without substantial interference with transmural fluid flow across the canal.
Description
FIELD

The devices, kits and methods described herein relate generally to intraocular pressure reduction. More particularly, the devices, kits and methods relate to intraocular implants implantable into Schlemm's canal that can reduce intraocular pressure without substantially interfering with fluid flow across Schlemm's canal.


BACKGROUND

Glaucoma is a potentially blinding disease that affects over 60 million people worldwide, or about 1-2% of the population. Typically, glaucoma is characterized by elevated intraocular pressure. Increased pressure in the eye can cause damage to the optic nerve which can lead to loss of vision if left untreated. Consistent reduction of intraocular pressure can slow down or stop progressive loss of vision associated with glaucoma. In addition, patients are often diagnosed with pre-glaucoma and ocular hypertension when they exhibit symptoms likely to lead to glaucoma, such as somewhat elevated intraocular pressure, but do not yet show indications of optic nerve damage. Treatments for glaucoma, pre-glaucoma and ocular hypertension primarily seek to reduce intraocular pressure.


Increased intraocular pressure is caused by sub-optimal efflux or drainage of fluid (aqueous humor) from the eye. Aqueous humor or fluid is a clear, colorless fluid that is continuously replenished in the eye. Aqueous humor is produced by the ciliary body, and then flows out primarily through the eye's trabecular meshwork. The trabecular meshwork extends circumferentially around the eye at the anterior chamber angle, or drainage angle, which is formed at the intersection between the peripheral iris or iris root, the anterior sclera or scleral spur and the peripheral cornea. The trabecular meshwork feeds outwardly into Schlemm's canal, a narrow circumferential passageway generally surrounding the exterior border of the trabecular meshwork. Positioned around and radially extending from Schlemm's canal are aqueous veins or collector channels that receive drained fluid. The net drainage or efflux of aqueous humor can be reduced as a result of decreased facility of outflow, decreased outflow through the trabecular meshwork and canal of Schlemm drainage apparatus, increased episcleral venous pressure, or possibly, increased production of aqueous humor. Flow out of the eye can be restricted by blockages or constriction in the trabecular meshwork and/or Schlemm's canal.


Glaucoma, pre-glaucoma and ocular hypertension currently can be treated by reducing intraocular pressure using one or more modalities, including medication, incisional surgery, laser surgery, cryosurgery, and other forms of surgery. In the United States, medications or medical therapy are typically the first lines of therapy. If medical therapy is not sufficiently effective, more invasive surgical treatments may be used. In other countries, such as those with socialized medical systems or with nationalized health care systems, surgery may be the first line of therapy if it is considered a more cost effective treatment.


A standard incisional surgical procedure to reduce intraocular pressure is trabeculectomy, or filtration surgery. This procedure involves creating a new drainage site for aqueous humor. Instead of naturally draining through the trabecular meshwork, a new drainage pathway is created by removing a portion of sclera and trabecular meshwork at the drainage angle. This creates an opening or passage between the anterior chamber and the subconjunctival space that is drained by conjunctival blood vessels and lymphatics. The new opening may be covered with sclera and/or conjunctiva to create a new reservoir called a bleb into which aqueous humor can drain. However, trabeculectomy carries both long and short term risks. These risks include blockage of the surgically-created opening through scarring or other mechanisms, hypotony or abnormally low intraocular pressure, expulsive hemorrhage, hyphema, intraocular infection or endophthalmitis, shallow anterior chamber angle, and others. Alternatives to trabeculectomy are actively being sought.


Bypass stents are also used to bridge a blocked trabecular meshwork. Stents can be inserted between the anterior chamber of the eye and Schlemm's canal, bypassing the trabecular meshwork. However, it is difficult to consistently and reliably implant a bypass stent from the anterior chamber into Schlemm's canal. The implant procedure is challenging and stents can become clogged and lose functionality over time. Others have inserted tubular elongated cylindrical hollow stents longitudinally into Schlemm's canal. Cylindrical hollow stents can be configured to allow circumferential fluid flow around the canal. These too can lose functionality over time as a result of occlusion or scarring.


Schlemm's canal is small, approximately 190-370 microns in cross-sectional diameter, and circular. Therefore, it can be difficult or expensive to design and manufacture hollow tubular stents of appropriate dimensions for use in opening Schlemm's canal. In addition, hollow tubular stents can be prone to failure and collapse or occlusion over time, as has been shown for cardiovascular stents. Hollow tubular stents incorporating thin walls are especially prone to failure. Further, the walls of tubular stents placed lengthwise along Schlemm's canal can have significant surface area contact with the trabecular meshwork and/or the collector channels, which can result in blockage of the meshwork or collector channels, substantially interfering with transmural flow across Schlemm's canal and into the eye's collector channels.


Therefore, easily manufacturable, minimally invasive devices for effective, long-term reduction in intraocular pressure are desirable. In addition, methods and kits incorporating such devices are desirable.


SUMMARY

Described here are devices, kits and methods for reducing intraocular pressure. The devices for reducing pressure within the eye comprise a support implantable circumferentially within Schlemm's canal that is configured to maintain the patency of at least a portion of the canal. The support occupies at least a portion of a central core of Schlemm's canal. The support does not substantially interfere with transmural flow across Schlemm's canal, and thereby utilizes the eye's natural drainage pathways. The support can be implanted into Schlemm's canal with minimal trauma to the eye.


The support generally comprises a biocompatible material. At least a portion of the support can be made from a biocompatible polymer, e.g., acrylics, silicones, polymethylmethacrylate, or a hydrogel. In addition, at least part of the support can be made from a biocompatible metal such as gold. In some variations, at least a portion of the support is made from a shape memory material. Suitable shape memory materials include shape memory polymers or shape memory alloys, such as nickel titanium alloys. If a shape memory material is used, the support can have a compressed state prior to and during implantation into Schlemm's canal, and an expanded state following implantation to open the canal.


In some variations, the support is at least partially made from a biocompatible, biodegradable polymer. The biodegradable polymer can be collagen, a collagen derivative, a poly(lactide); a poly(glycolide); a poly(lactide-co-glycolide); a poly(lactic acid); a poly(glycolic acid); a poly(lactic acid-co-glycolic acid); a poly(lactide)/poly(ethylene glycol) copolymer; a poly(glycolide)/poly(ethylene glycol) copolymer; a poly(lactide-co-glycolide)/poly(ethylene glycol) copolymer; a poly(lactic acid)/poly(ethylene glycol) copolymer; a poly(glycolic acid)/poly(ethylene glycol) copolymer; a poly(lactic acid-co-glycolic acid)/poly(ethylene glycol) copolymer; a poly(caprolactone); a poly(caprolactone)/poly(ethylene glycol) copolymer; a polyorthoester; a poly(phosphazene); a poly(hydroxybutyrate) or a copolymer including a poly(hydroxybutyrate); a poly(lactide-co-caprolactone); a polycarbonate; a poly(esteramide); a polyanhydride; a poly(dioxanone); a poly(alkylene alkylate); a copolymer of polyethylene glycol and a polyorthoester; a biodegradable polyurethane; a poly(amino acid); a polyetherester; a polyacetal; a polycyanoacrylate; a poly(oxyethylene)/poly(oxypropylene) copolymer; and blends and copolymers thereof.


The support can comprise an active agent. For example, a support can be coated or impregnated with an active agent. Alternatively, an active agent can be dispersed within the support, e.g., by filling a cavity within the support. The active agent can include a prostaglandin, a prostaglandin analog, a beta blocker, an alpha-2 agonist, a calcium channel blocker, a carbonic anhydrase inhibitor, a growth factor, an anti-metabolite, a chemotherapeutic agent, a steroid, an antagonist of a growth factor, or combinations thereof. The release of the active agent can be controlled using a time release system, e.g., by embedding or encapsulating the active agent with a time release composition.


In some variations, the support will be solid. In other variations, at least a portion of the support will be hollow or porous. The surface of the support may be smooth, rough, spiked, or fluted. In still other variations, at least part of the support will be made from mesh. The support can include at least one fenestration and one or more rod-like members.


In some variations, the support comprises at least two adjacent beads. Adjacent beads can have the same or different sizes and shapes, and can be made from the same or different materials. The bead shapes can be spherical, spheroid, ovoid, cylindrical, cuboid, cubical, conical, discoid, helical, or segments thereof. In some variations, there is a connector linking at least two adjacent beads together. If there is a connector, it can be rigid or flexible. If there is more than one connector, e.g., two connectors inserted between three beads, the connectors may be of the same or different lengths. The connectors can include the same or different material as the beads they connect. A connector can also function as a spacer configured to provide space between adjacent beads. In some variations, the support comprises at least two discs separated by, and connected with, a connector. The discs may include fenestrations. The connector may also comprise a guide wire over which a fenestrated bead can be threaded into the canal of Schlemm.


The support can extend approximately all the way around Schlemm's canal, if the support has a circumference approximately equal to the circumference of Schlemm's canal. Alternatively, the support can extend only about half way around the circumference of Schlemm's canal, or about a quarter way around the canal. In some variations, the support will extend less than a quarter circumference of Schlemm's canal. The support can be configured to contact the inner surface of the wall of Schlemm's canal at two, three or more points. In some variations, the support can be attached to tissue. The support may comprise a stiff arcuate member having a radius of curvature smaller or larger than that of Schlemm's canal.


In some variations, the support can be altered using electromagnetic radiation. For example, a laser having a wavelength absorbable by at least one localized portion of the support can be used to alter the support. In other variations, electromagnetic radiation can be used to release an active agent from the support. In still other variations, the support can be visually enhanced using fluorescence or phosphorescence emission. For example, the support can comprise a chromophore that fluoresces or phosphoresces upon excitation with a light source. In some variations, the emitted fluorescence or phosphorescence is in the wavelength range of about 300 nm to about 800 nm. In some variations, the support can comprise a chromophore that enhances postoperative monitoring of the support.


Kits for reducing intraocular pressure are also provided. The kits contain a support that can be implanted circumferentially within Schlemm's canal. The support is configured to maintain the patency of at least part of Schlemm's canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. The kits also contain an introducer for implanting the support within the canal. In some variations, the kits include a positioning device for adjusting the support within the canal. In other variations, kits include instructions. In still other variations, the kits include an active agent. Some kits contain at least two supports. If more than one support is included, the kits can include at least two introducers for delivering the supports. Multiple supports within the same kit can have the same or different shape, size, or composition. Multiple supports within the same kit can be connected together or remain separate. In some variations, kits include a fixation device for attaching a support to tissue. In other variations, kits may include a system for visually enhancing the appearance of the support.


Methods for reducing intraocular pressure are also described. The methods include inserting a support circumferentially within Schlemm's canal. The support is configured to maintain the patency of at least part of the canal. The support occupies at least a portion of a central core of Schlemm's canal, and does not substantially interfere with transmural flow across the canal. In some variations, the methods also include dilating Schlemm's canal prior to insertion of the support. In still other variations, the methods comprise anchoring the support to tissue. The methods can include implanting at least two supports. If more than one support is implanted within a single eye, the multiple supports can be positioned circumferentially adjacent to each other or circumferentially opposed (i.e., positioned about 180° apart) to each other within Schlemm's canal. Multiple supports within one eye can be connected or remain separate. In some variations of the methods, the support is illuminated with a light source to visually enhance the position of the support. In other variations of the methods, the support can be altered using electromagnetic radiation. For example, a laser absorbed by at least one localized portion of the support can be used to alter the support. The alteration can comprise the creation or enlargement of an aperture in the support. If electromagnetic radiation is used to alter a support, the alteration can occur before implantation or after implantation.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 provides a partial cross-sectional side view of a normal human eye.



FIG. 2 provides a partial cross-sectional side view of a normal drainage path of fluid from the eye.



FIG. 3 shows a front view of normal fluid drainage from the eye.



FIG. 4A shows an alternative front view of normal fluid drainage paths from the eye. FIG. 4B shows a cross-sectional view along line I-I′.



FIG. 5A provides a front view of an eye in which Schlemm's canal is narrowed or collapsed. FIG. 5B shows a front view of a device including a support inserted into Schlemm's canal that allows transmural flow across the canal. FIG. 5C illustrates an alternate design for a device inserted into Schlemm's canal that allows transmural flow across the canal.



FIG. 6A shows side views of various element or bead configurations that can be used in the supports described herein. FIG. 6B shows the corresponding front views of the element or bead configurations shown in FIG. 6A. FIG. 6C illustrates an element or bead having fenestrations.



FIG. 7A illustrates a support having multiple juxtaposed beads. FIG. 7B illustrates a support having multiple juxtaposed and connected beads. FIG. 7C shows an alternate configuration of a support having multiple juxtaposed and connected beads. FIG. 7D shows a support having multiple, spaced-apart but connected beads. FIG. 7E illustrates beads threaded onto a connector.



FIGS. 8A-B show side and front views, respectively, of a support having an open network structure. FIGS. 8C-D show side and front views, respectively, of a support having a longitudinal zig-zag configuration that will contact the wall of Schlemm's canal at at least three points (labeled P1, P2, P3). FIGS. 8E-F show side and front views, respectively, of a support having a rod-like member with continuously fluted edges and fenestrations. FIGS. 8G-H show side and front views, respectively, of another variation of a support having a rod-like member with continuously fluted edges.



FIGS. 9A-B show expanded cross-sectional views of a support implanted within Schlemm's canal.



FIGS. 10A-C illustrate various configurations of supports implanted into Schlemm's canal.



FIGS. 11A-B illustrate two configurations of supports having a smaller radius of curvature than Schlemm's canal. FIG. 11C shows a support having a larger radius of curvature than Schlemm's canal.



FIG. 12A illustrates a variation of a support traversing the center of the central core of Schlemm's canal. FIG. 12B shows a cross-sectional view along line II-II′. FIG. 12C illustrates a variation of a support traversing the central core of the canal. FIG. 12D shows a cross-sectional view along line III-III′. FIG. 12E illustrates a variation of a support that occupies the majority of the central core of the canal. FIG. 12F shows a cross-sectional view along line IV-IV′. FIG. 12G illustrates a variation of support having an open network that occupies a portion of the central core of the canal. FIG. 12H shows a cross-sectional view along line V-V′.



FIG. 13 shows an illustrative example of a support that can be modified using electromagnetic radiation.



FIG. 14A illustrates a syringe that can be used to insert a support into Schlemm's canal.



FIG. 14B illustrates a variation in which a support is threaded onto a guide element for insertion and positioning in Schlemm's canal. FIG. 14C illustrates a cross-sectional view of a support having a central bore to accommodate a guide element. FIG. 14D illustrates a variation in which a syringe and a guide element are used for insertion and positioning of a support in Schlemm's canal.





DETAILED DESCRIPTION

Described here are devices, kits and methods to reduce intraocular pressure by maintaining or restoring Schlemm's canal so that at least a portion of the canal is patent or unobstructed. The devices, kits and methods operate to keep Schlemm's canal from collapsing while not substantially interfering with the eye's natural drainage mechanism for aqueous humor, in which transmural fluid flow across Schlemm's canal occurs. The devices are implantable in Schlemm's canal with minimal trauma to the eye.


With reference to the figures, FIG. 1 shows a partial cross-sectional view of the anatomy of a normal human eye. Ciliary body 12 is connected to iris 18 and to lens 16 via zonular fibrils 14. The anterior chamber of the eye 20 is bounded on its anterior (front) surface by cornea 24. In the center of iris 18 is pupil 22. Cornea 24 is connected on its periphery to sclera 26, which is a tough fibrous tissue forming the white shell of the eye. Trabecular meshwork 28 is located on the outer peripheral surface of anterior chamber 20. The trabecular meshwork extends 360° circumferentially around the anterior chamber. Located on the outer peripheral surface of meshwork 28 is Schlemm's canal 30. Schlemm's canal extends 360° circumferentially around the trabecular meshwork. At the apex formed between iris 18, meshwork 28 and sclera 26 is angle 32. Conjunctiva 34 is a membrane overlaying sclera 26 and lining the inside of the eyelid (not shown).



FIG. 2 shows a partial cross-sectional view of flow of aqueous humor within and out of a normally functioning human eye. Aqueous humor is produced in ciliary body 12 and its path through and out of the eye is indicated by solid directional line 36. The aqueous humor flows from ciliary body 12, between lens 16 and iris 18, through pupil 22 into anterior chamber 20, across trabecular meshwork 28, across Schlemm's canal 30, into aqueous veins or collector channels (not shown) and finally into the bloodstream via conjunctival vasculature.



FIG. 3 shows a front view of normal flow of aqueous humor out of the eye. Aqueous humor enters anterior chamber 20 via pupil 22. The fluid flows outwardly toward the periphery of the eye, with the general path of flow indicated by solid directional lines 36. The fluid crosses trabecular meshwork 28 and traverses Schlemm's canal 30 to reach aqueous veins or collector channels 38. There are typically 25-30 collector channels located in a human eye. Collector channels 38 are connected to vasculature 40, whereby the drained aqueous humor enters the bloodstream. Although the direction of net or bulk fluid flow is depicted as radially outward by directional lines 36 from pupil 22 for simplicity, actual fluid flow in an eye may follow more varied paths.


Different fluid flow paths in and across Schlemm's canal are illustrated in FIGS. 4A-B. FIG. 4A shows a front view of an eye, and FIG. 4B shows an expanded cross-sectional view along line I-I′. Circumferential (i.e., longitudinal) flow along and around circular canal 30 is depicted by directional lines 50. Fluid that does not traverse canal 30 to reach collector channels 38 may not be effectively drained from the eye. Examples of fluid flow paths that can effectively drain the eye are illustrated by directional lines 52, 52′, and 52″. In each of these paths, fluid enters trabecular meshwork 28 along its inner peripheral surface 60 and exits the meshwork along its outer peripheral surface 62′. Meshwork outer peripheral surface 62′ provides the inner peripheral surface or wall of Schlemm's canal 30. Transmural fluid flow across Schlemm's canal involves two instances of transmural flow across walls or boundaries. First, fluid must flow from trabecular meshwork 38 through inner peripheral surface or wall 62′ of Schlemm's canal 30 to reach lumen 64 of the canal. Second, fluid must flow from lumen 64 through canal outer peripheral wall 62″ through apertures 38′ to enter collector channels 38. Finally, the collector channels 38 feed the drained fluid into vasculature. Lumen 64 of canal 30 includes a central core region 67. Thus, fluid flow from the eye differs from fluid flow in other vessels in the body where fluid need only flow longitudinally along the vessel, such as blood flowing through a vein.


Devices

Devices to reduce intraocular pressure comprising a support that can be implanted circumferentially in Schlemm's canal to maintain the patency of at least a portion of the canal are described here. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. By “maintain the patency” of at least a portion the canal, it is meant that the support operates to keep the canal at least partially unobstructed to transmural flow, such that fluid can 1) exit through the trabecular meshwork; 2) traverse the canal; and 3) drain via the collector channels. To maintain the patency of the canal, it is not necessary that the support leave the canal unobstructed in regard to circumferential flow. By “does not substantially interfere” with transmural flow, it is meant that the support does not significantly block either fluid outflow from the trabecular meshwork or fluid outflow to the collector channels. In many variations, the support allows between about 0.1 and about 5 microliters per minute aqueous outflux from the eye through the trabecular meshwork and collector channels. The “central core of Schlemm's canal” refers to the region around the cross-sectional center of the canal in the interior space of the canal lumen, i.e., not on the periphery of the canal. Therefore, a device that occupies at least a portion of a central core of Schlemm's canal can traverse at least a portion of the canal's lumen.


Therefore, devices described here need not comprise an open-ended tubular support placed longitudinally along Schlemm's canal, i.e., the devices and supports can be non-tubular. A longitudinal, open-ended tubular support can enable longitudinal flow along the canal. However, even if fluid can flow longitudinally (i.e., circumferentially) along Schlemm's canal, the eye may not be effectively drained unless the fluid eventually traverses the canal. That is, transmural fluid flow across two boundaries must occur: 1) fluid must flow from the trabecular meshwork through a canal inner wall coincident with an outer peripheral boundary of the trabecular meshwork to reach the canal lumen; and 2) fluid must flow from the canal lumen through apertures in the canal outer peripheral wall to reach the connector channels. The collector channels are then able to further disperse the fluid and complete the natural draining process. A tubular support inserted longitudinally into the canal can have significant surface area overlap with surfaces of the canal such that transmural flow across the canal may be significantly impeded. A longitudinal tubular support placed in Schlemm's canal may block flow into the canal from the trabecular meshwork and block flow out of the canal into the collector channels.


Devices described herein for treating elevated intraocular pressure include a support that is implanted within Schlemm's canal. In many instances, the device will reduce the intraocular pressure by 1-40 mm Hg, for example by at least 2 mm Hg. In other instances, the device will reduce intraocular pressure by at least 4 mm Hg, or at least 6 mm Hg, or at least 10 or 20 mm Hg. In still other instances, the device will operate to bring the intraocular pressure into the range of about 8 to about 22 mm Hg. The support can be configured in a variety of ways to at least partially prop open Schlemm's canal thereby maintaining its patency without substantially interfering with or impeding transmural fluid flow across Schlemm's canal. In some variations, the support may interfere with or block longitudinal flow along or around the canal. In many instances, the support will be contained entirely within Schlemm's canal. In some variations the support will be implanted within the canal, but may extend partially beyond Schlemm's canal, e.g., into the trabecular meshwork.


In some variations, a support to maintain at least partial patency for Schlemm's canal to enable fluid flow between an inner wall of the canal and an outer wall of the canal can comprise elements or structures such as bead-like elements or beads, which can be connected together, e.g., as a string of beads. Individual elements or beads or a connected group of elements or beads can be inserted directly into Schlemm's canal. A more detailed description of supports incorporating elements or beads is provided below.



FIG. 5A illustrates a front view of an eye having a narrowed or collapsed Schlemm's canal 30, where canal outer peripheral wall 62″ is very close to canal inner peripheral wall 62′. Although Schlemm's canal 30 is depicted in FIG. 5A as being uniformly narrow around the entire circumference of canal, it is possible that only a portion of Schlemm's canal is narrowed or collapsed. When Schlemm's canal is collapsed or narrowed, net efflux of aqueous from the anterior chamber to the collector channels 38 is diminished, thereby increasing intraocular pressure. As a result, the risk of pre-glaucoma, ocular hypertension, or glaucoma can increase.



FIG. 5B illustrates an example of a device 70 inserted into Schlemm's canal 30 through incision site 74. Device 70 in this example is positioned to one side of incision site 74. Device 70 includes support 72 that is configured to keep Schlemm's canal at least partially open to transmural fluid flow across both canal inner wall 62′ and canal outer wall 62″ to reach collector channels 38 via apertures 38′. In the example shown in FIG. 5B, support 72 includes elements or beads 76 connected with connectors 78. In this variation, the distance between canal inner wall 62′ and outer wall 62″ is approximately determined by the cross-sectional dimension of support 72, which is in turn determined by the largest cross-sectional diameter of the beads 76. Therefore, circumferential (i.e., longitudinal) fluid flow around and along the canal 30 indicated by directional line 50 may be inhibited by the insertion of support 72 into the canal. However, transmural flow across both walls or boundaries of the canal indicated by directional lines 52, 52′, 52″ is enhanced by support 72 and fluid is able to reach collector channels 38 and be drained from the eye. As a result, support 72 can effectively reduce intraocular pressure by utilizing the eye's natural drainage mechanism. Incision 74 need only be large enough to accommodate the diameter of beads 76, so that trauma to the eye is minimized. Beads can have cross-sectional dimensions in the range from about 50 microns to about 500 microns. Insertion of beads having relatively small cross-sectional diameters (e.g., about 50 microns) into Schlemm's canal open the canal less than the normal cross-sectional diameter of the canal, which is about 190 to about 370 microns, but still can maintain the patency of the canal. Insertion of beads having relatively large cross-sectional diameters (e.g., greater than about 300 microns) can open the canal as large as or larger than the canal's normal cross-sectional diameter and also can operate to stretch the trabecular meshwork. Stretching the trabecular meshwork may further enhance drainage.



FIG. 5C illustrates an alternate configuration of a device 80 inserted into Schlemm's canal 30 through incision site 84. Device 80 includes support 82 that extends to both sides of incision site 84. Support 82 includes elements or beads 76 connected with connectors 88 and 88′. In this example, connector 88′ is of a different length than connectors 88. As in FIG. 5B, beads 76 may impede circumferential (i.e., longitudinal) fluid flow around and along canal 30 indicated by directional line 50. However transmural flow across the canal is enhanced by support 82 that maintains patency across the canal and allows fluid to reach collector channels 38. If the beads are fenestrated or comprise rough, spiked, or fluted perimeters, then circumferential fluid flow through or around the beads may also occur.


Elements or beads used in a support may be hollow and closed structures, open structures, solid structures, porous structures, or any combination thereof, and may be of any suitable shape. FIGS. 6A and 6B illustrate side and front views, respectively, of exemplary elements or beads that may be used in the supports described here. As shown, solid 90 or hollow 91, spherical 90, spheroid 92, ovoid 93, conical 94, disk-shaped 95, polyhedral 96, rod-like 97, or beads with fluted edges 98, rough edges, 89, or spiked edges 88 may be used. In some instances, it may be desired to round corners or edges of the beads. As illustrated in FIG. 6C, elements or beads 76 may include fenestrations 99, 99′. Fenestrations may have any suitable cross-sectional shape, such as round or quadrilateral. Although a disc-shaped bead 76 is shown in FIG. 6C, any shape of bead can be fenestrated.


As illustrated in the variations shown in FIGS. 7A-E, two or more beads 76 in a support may be adjacent to each other. Adjacent beads may be juxtaposed (FIG. 7A), connected and juxtaposed (FIGS. 7B and 7C), or connected together with connectors 100, 100′ to form intervals between beads (FIG. 7D). In addition, beads may be threaded onto a connector 101 (FIG. 7E). Multiple beads used in a single support may have the same or different shapes, and may be made of the same or different materials.


Junctions 102 between beads as shown in FIG. 7B can be made using any suitable technique, such as by using an adhesive, chemical bonding, mechanical interlocking, or welding. Beads may also be juxtaposed and connected as shown in FIG. 7C by threading onto a guide element 104. Guide element 104 can comprise a fiber, a suture, a guide wire, a fixture, or the like. The beads can be fixed in a juxtaposed configuration on a guide element, e.g., by knotting ends of the fiber or by providing other end-blocking devices 106, such as clips, caps, protrusions, or the like on ends 108 of element 104. Any or all of the beads can be attached to guide element 104, e.g., beads occupying end positions may be attached to element 104 and function as blocking beads to keep beads from sliding off ends 108 of element 104. Alternatively, beads may slide along element 104. Guide element 104 can be flexible, such as thin polymer threads, such as a suture, or metal wires. Alternatively, element 104 can be flexible but fixable, such as one or more shapeable metal wires that can be bent into a desired position and maintain that position against some amount of external stress or pressure. In other variations, guide element 104 can be rigid, e.g., a molded polymeric piece or a stiff metal piece.


As shown in FIG. 7D, multiple connectors 100, 100′ may be used in a single support, with at least one connector inserted between adjacent beads 76. If multiple connectors are used, they may be of the same or different lengths. In addition, multiple connectors within the same support may be made of the same or different materials, and the connectors may be made of the same or different materials than the beads. Discrete connectors 100, 100′ can be inserted between beads 76 and attached to adjacent beads using any suitable method including using adhesives, chemical bonding, welding, mechanical interlocking, knots, or any combination thereof. In some variations, connectors 100, 100′ between beads can be configured to function as spacers between individual beads. As illustrated in FIG. 7E, beads 76 can also be threaded onto a connector 101. If the beads are threaded onto a connector, the beads can be maintained in fixed positions along the connector 101 by any suitable method, including using adhesives, chemical bonding, welding, clips, protrusions on the connector, mechanical interlocking locking between a connector and a bead, knots, or any combination thereof. Alternatively, some or all beads may slide along connector 101. Connectors 100, 100′, 101 can be flexible, such as thin polymer threads or metal wires. Connectors 100, 100′, 101 can also be flexible but fixable, such as shapeable metal wires. Alternatively, connectors 100, 100′, 101 may be rigid, such as molded polymeric connectors or stiff metal connectors.


Supports of the devices described here need not contain beads. For example, a support can be a unitary structure of fixed or variable length. Supports can be solid, hollow, or porous, or any combination thereof. For example, a support can be partially solid and partially hollow. Examples of support configurations are shown in side view and front view in FIGS. 8A-F. As illustrated in FIG. 8A-B, a support can have an open network structure. Such a support can be fabricated out of shapeable metal wires, for example. The support illustrated in FIGS. 8A-B will have minimal surface area contact with the walls of Schlemm's canal, i.e., only point contacts at the end of wires or fibers 170. Alternatively, a support having an open network structure can be at least partially made from a mesh or foam. The mesh or foam can be made of any suitable material, e.g., metal or plastic. As shown in FIGS. 8C-D, the support can have a sinusoidal or zig-zag configuration extending along a selected length of Schlemm's canal. For the example shown in FIG. 8C, the support will contact the wall of Schlemm's canal at at least three points, labeled P1, P2, and P3, after implantation. In FIGS. 8E-H, examples of rod-like supports having fluted edges are shown. In FIGS. 8E-F, fluted edges 110 extend longitudinally along sides 112 between ends 114 of the support to form structures 116. Structures 116 can include fenestrations 113. The support can include central bore 117. In FIGS. 8G-H, fluted edges 110′ extend along sides 112′ to form structures 116′. Structures 116′ have serrated outer surfaces 115′ extending between ends 114′. The support can include central bore 117′. In the variations illustrated in FIGS. 8E-H, the support may contact the canal walls at at least four points. In some variations, the support is adjustable.


A common characteristic of the support configurations described here is that they need not have continuous or extensive contact with a wall of Schlemm's canal. Indeed, many of the described devices and structures have minimal tangential, periodic, or sporadic contact with the wall. The surface of the support can be rough, smooth, spiked or fluted. As the example shown in FIGS. 8A-B shows, some supports only have point contacts with the canal wall. For the supports shown in FIGS. 5B-C, the rounded beads of each of the supports make only tangential contact with the canal wall. Bead shapes can be selected or designed to have minimal surface area contact with canal walls, e.g., beads 98 having fluted edges as shown in FIGS. 6A-B may have low surface area contact with canal walls. In addition, supports having widely spaced apart beads, e.g., by connectors illustrated in FIGS. 7D-E that can function to space beads at desired intervals to reduce contact with canal walls yet operate to keep the canal open. As illustrated above with respect to FIGS. 8C-D, in some variations, the support contacts the interior wall of the canal at at least two points; or at at least three points.


Expanded cross-sectional views of a support 152 implanted circumferentially in Schlemm's canal are provided FIGS. 9A-B. The fraction of canal wall surface area in contact with a support can be estimated by viewing the inside of Schlemm's canal as a slightly arcuate cylinder C having length L, extending circumferentially from a first end X1 to a second end X2 of support 152, and inside radius Ri. In some variations, the support contacts less than 0.1% or less than 1% of the surface area of the cylinder C as described above. In other variations, the support contacts less than 10% of the surface area of C. In still other variations, the support contacts less than 30% of the surface area of C. For example, the support 152 shown in FIGS. 9A-B contacts the canal wall 62 only at bead outer peripheral edges at E1-E7, along a distance of the bead width BW. There is no contact with the canal walls where connectors 156 space apart beads 154, and no contact in fluted regions 160 of beads 154. The design feature of minimal support contact with canal walls allows a support to maintain patency of the canal without substantially interfering with transmural flow across the canal. If a substantial portion of the surface area of the inner periphery of the canal adjacent to the trabecular network or of the surface area of the outer periphery of the canal where the collector channels are located is blocked, effective fluid flow across the canal may be impaired.


Supports can have variable lengths and thicknesses. For example, the length of supports using beads can be tuned by varying the number, type, or spacing of beads, or any combination thereof. The thickness of a support can be increased by adding one or more beads having larger dimensions. Unitary supports can also be built with varying lengths, or with adjustable (e.g., trimmable) dimensions. For example, for a support made of shapeable metal having a sinusoidal or zig-zag configuration as shown FIGS. 8C-D, a cross-sectional dimension 117 of the support can be decreased or increased by apply tension along dimension 119. As illustrated in FIG. 10A, a support 160 can extend essentially around the entire circumference of Schlemm's canal 30. Alternatively, a support can extend approximately half way around the circumference of the canal (not shown). As shown in FIG. 10B, a support 162 can extend less than half way around the canal. As shown in FIG. 10C, a support 164 can extend a quarter or less of the circumference around the canal. In addition, more than one support 164, 166, 168 can be inserted into a single Schlemm's canal. If multiple supports are inserted into a single canal, they can be of different shapes, lengths, materials or sizes.


A support can be configured such that it will open the canal beyond a maximum cross-sectional dimension of the support itself. For example, as illustrated in FIG. 11A, device 130 comprising support 132 is inserted into Schlemm's canal 30. Support 132 comprises beads 134 which have a maximum cross-sectional dimension BD. Support 132 comprises a stiff arcuate element 135 with a radius of curvature Rsupp smaller than the radius of curvature of Schlemm's canal RSC. The smaller, fixed radius of curvature Rsupp of arcuate member135 urges canal 30 to open more than BD. In another variation shown in FIG. 11B, support 179 comprises an arcuate member 180 without beads having a radius of curvature Rsupp that is less than the radius of curvature RSC of the canal. Member 180 is sufficiently stiff to urge the canal open. In another variation shown in FIG. 11C, support 181 comprises an arcuate member 182 having a radius of curvature Rsupp larger than that of Schlemm's canal RSC. Member 182 is also sufficiently stiff to urge the canal open. Arcuate members 135, 180 and 182 can comprise a shape memory material such as Nitinol, for example. As indicated in FIG. 11C, support 181 can include beads 184. To urge open the canal, the radius of curvature Rsupp of an arcuate members can be about 10%, 20%, 30%, 40%, or 50% or smaller or larger than that of Schlemm's canal RSC. For example, an arcuate member can have a radius of curvature of about 3 mm to about 8 mm. In some variations, the radius of curvature of an arcuate member Rsupp in a support is about 3 mm, or about 4 mm, or about 5 mm. In other variations, the radius of curvature Rsupp of an arcuate member in a support is about 6 mm, or about 7 mm, or about 8 mm.


The supports described here occupy at least a portion of a central core of Schlemm's canal. The central core of Schlemm's canal is the region around the cross-sectional center of the canal in the interior space of the canal lumen. A support that occupies at least a portion of the central core of the canal can traverse at least a portion of the canal lumen. For example, some variations of supports can traverse the cross-sectional center of the canal at at least one point. Referring to FIG. 12A, a front view of a support 220 having beads 222 connected with connectors 224 is provided. FIG. 12B shows an expanded cross-sectional view along line II-II′. Support 220 occupies a portion canal central core 67 in canal lumen 64. Trabecular meshwork 28 is shown adjacent to canal 30. In this variation, support 220 traverses the cross-sectional center 66 of the canal. In other variations, supports can traverse the lumen of the canal off-center, e.g., appearing as a chord across the canal lumen in cross-section. Referring to FIG. 12C, a front view of an arcuate support 210 is shown. FIG. 12D shows an expanded cross-sectional view along line III-III′. Support 210 traverses and occupies a portion of central core 67 in lumen 64 of canal 30 without passing through canal center 66. In some variations, the support can occupy the majority of the central core of the canal. Referring to FIG. 12E, a front view of support 230 comprising disc-like beads 232 is shown. A cross-sectional view along line IV-IV′ is shown in FIG. 12F. As illustrated in FIG. 12F, bead 232 with fenestrations 234 occupies the majority of central core 67 of canal 30. In other variations, the support occupies only a small portion of the central core of the canal. For example, in FIG. 12G, a front view of a support 240 having an open network structure is shown. A cross-sectional view along line V-V′ is shown in FIG. 12H.


A support can made of a variety of different materials. In general, the support should comprise a biocompatible material, such as a biocompatible polymer, ceramic or ceramic composite, glass or glass composite, metal, or combinations of these materials. Examples of biocompatible metals include stainless steel, gold, silver, titanium, tantalum, platinum and alloys thereof, cobalt and chromium alloys, and titanium nickel alloys such as Nitinol. Examples of biocompatible polymers include high density polyethylene, polyurethane, polycarbonate, polypropylene, polymethylmethacrylate, polybutylmethacryate, polyesters, polytetrafluoroethylene, silicone, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl chloride, ethyl vinyl acetate, collagen, collagen derivatives, flexible fused silica, polyolefins, NYLON® polymer, polyimide, polyacrylamide, fluorinated elastomers, and copolymers and blends thereof. In addition, biocompatible hydrogels can be used in supports and devices described herein. As discussed in more detail below, biocompatible polymers may be biodegradable. A support can be made of a single material or a combination of materials. In some variations, a support made from a first material is coated with a second material, e.g., to enhance or improve its biocompatibility.


In some examples, the biocompatible polymer in a support will include a biodegradable polymer. Examples of suitable biodegradable polymers include collagen, a collagen derivative, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a poly(lactide)/poly(ethylene glycol) copolymer, a poly(glycolide)/poly(ethylene glycol) copolymer, a poly(lactide-co-glycolide)/polyethylene glycol) copolymer, a poly(lactic acid)/poly(ethylene glycol) copolymer, a poly(glycolic acid)/poly(ethylene glycol) copolymer, a poly(lactic acid-co-glycolic acid)/poly(ethylene glycol) copolymer, a poly(caprolactone), a poly(caprolactone)poly(ethylene glycol) copolymer, a polyorthoester, a poly(phosphazene), a poly(hydroxybutyrate) or a copolymer including a poly(hdroxybutyrate), a poly(lactide-co-caprolactone), a polycarbonate, a poly(esteramide), a polyanydride, a poly(dioxanone), a poly(alykylene alkylate), a copolymer of polyethylene glycol and a polyorthoester, a biodegradable polyurethane, a poly(amino acid), a polyetherester, a polyacetal, a polycyanoacrylate, a poly(oxyethylene)/poly(oxypropylene) copolymer, and blends and copolymers thereof.


At least a portion of the support can be made from a shape memory material. For example, shape memory alloys, e.g. a nickel-titanium alloy can be used. In addition, shape memory polymers, e.g., polymers made from copolymerizing monomers oligo(e-caprolactone) dimethacrylate and n-butyl acrylate or polymers based on styrene acrylate, cyanate ester and epoxies, can be used. If a shape memory material is used in the support, the support can have a compressed state prior to and during implantation, and an expanded state following implantation. The use of a compressed state support comprising a shape memory material can allow for a smaller incision and facilitate insertion into a narrowed or compressed Schlemm's canal. Once implanted, the support can be expanding using any suitable method, e.g., thermally activated by body heat or an alternate heat source, to adopt an expanded state, thereby opening the canal.


The support can include an active agent, such as a pharmaceutical. Active agents can include prostaglandins, prostaglandin analogs, beta blockers, alpha-2 agonists, calcium channel blockers, carbonic anhydrase inhibitors, growth factors, such as tissue growth factors and vascular endothelial growth factors, anti-metabolites, chemotherapeutic agents such as mitomycin-C,5-fluorouracil, steroids, antagonists of growth factors such as antagonists of vascular endothelial growth factors, or combinations thereof. The active agent can be provided as a coating on at least a portion of a support. The active agent can be delivered throughout the eye by dissolution or other dispersal mechanisms. Alternatively, at least a portion of the support can be impregnated with the active agent. In other embodiments, the active agent can be dispersed within at least a portion of the support. For example, a cavity in the support can be filled with the active agent.


The delivery of the active agent can be controlled by time-release. For example, the portion of the support containing the active agent can include a time release coating or time release formulation designed to gradually dissipate the active agent over a certain period of time. Biodegradable coatings and formulations for time-release of active agents are known in the art. In some variations, the support can comprise multiple layers, where the layers each comprise an active agent. For example, support layers can be used to release a series of different agents, or a series of doses of the same agent. Such layers can be part of a coating applied to a support, or part of a support body. In addition, the support can comprise biodegradable layers containing no active agent that can be applied or interspersed between other layers to further control delivery of active agents to the eye.


In some variations, it will be desirable to change or alter the support using electromagnetic radiation. For example, at least a portion of a support can be fenestrated, perforated, bent, shaped or formed using a laser to enhance intraocular pressure reduction. As illustrated in FIG. 13, predetermined localized portions 120 of support 122 can be designed to absorb light of a certain wavelength or wavelength range. Preferential absorption can be achieved by material selection and/or by doping with chromophores. Upon irradiation with sufficient energy at the selected wavelength or wavelength range, the patterned regions 120 will ablate or melt, leaving new or enlarged perforations or indentations in the support. For example, a pulsed titanium sapphire laser operating between about 750 and about 800 nm can be used to ablate gold regions. If beads 126 in support 120 are hollow, then after irradiation and ablation, features 120 will become fenestrations. The fenestrations can be created to make support 122 more porous in nature or to allow release of an active agent from within a support, e.g., from within beads 126. Alternatively, it is possible to use a mask in combination with electromagnetic radiation to alter a support, such as by patterning or machining. The modification of a support using electromagnetic radiation can be carried out prior to or subsequent to insertion.


In some variations, the visual appearance of the support can be enhanced under certain conditions to facilitate placement or to monitor the position or condition of the support. Visual enhancement can be achieved by incorporating into or onto the support chromophores that fluoresce or phosphoresce upon excitation with a light source. Chromophores can also assist a clinician in verifying the position of the support postoperatively using a gonioscope, for example. Light sources can include lasers, lamps, and light emitting diodes. In some instances, transmission or absorption filters may be used to select the wavelength of the excitation source or to detect or view emission. Emission from a support capable of visual enhancement may be in the wavelength range of about 300 nm to about 800 nm. The chromophores can be an integral component of the material making up the support, doped into support material, or coated or sprayed onto the support. Visually-enhancing chromophores can be applied on a temporary basis, or on a permanent basis. An example of a suitable chromophore is fluorescein, which can be excited with any laser or lamp emitting at about 400 to about 500 nm. In addition, phosphorus-based chemiluminescent or photoluminscent pigments can be used, which can be selected to absorb at various wavelengths across the visible spectrum.


In some variations, the support may be capable of being attached to tissue. For example, the support may include a hook, loop, clip, extension, or the like that may be easily attached to tissue. The support may also be attached to tissue using sutures or adhesives. The support may be attached to tissue using more than one attachment method, e.g., suturing may be used in combination with a loop, or an adhesive may be used in combination with a hook. In other variations, the support may be allowed to self-position in Schlemm's canal. In still other variations, the support may be mobile within Schlemm's canal.


Kits

Kits for reducing intraocular pressure are provided, where the kits contain at least one support that can be implanted circumferentially within Schlemm's canal configured to maintain the patency of at least a portion of Schlemm's canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across the canal. The kits also provide an introducer or delivery device for implanting the support in the canal. The support and introducer are provided in packaged combination in the kits. The kits can also include instructions for use, e.g., for implanting and inspecting the support.


The introducer can be inserted into the eye and is capable of implanting the support at the desired implantation position within Schlemm's canal. For example, an introducer may include a tubular cannula through which the support may be passed. In addition to a cannula, the introducer may include a tubular or solid pusher rod that can be used to push or advance the support into and/or around Schlemm's canal. Alternatively, a pusher rod or plunger can be used without a cannula to introduce a support into the canal. A support can be installed into the lumen of a cannula prior to insertion, the distal end of the cannula positioned at or near the desired support location, and the pusher rod operated from the proximal end to push the support distally out of the distal end of the cannula and into the canal. The cannula and/or the pusher rod may be flexible and small enough in diameter to extend at least partially around the canal. In some variations, a proximal end of a suture can be introduced into the canal via a cannula and the suture extended circumferentially around the canal. A distal portion of the suture can be connected to the support and force applied to the proximal end of the suture to pull the support into the canal. The support can then be positioned within the canal by pulling the suture in a distal or proximal direction. The suture can be used to anchor the support within the canal. In other variations, the support can be directly introduced into the canal using surgical forceps, or the like.



FIGS. 14A-D illustrate additional variations for introducing a support into the canal. As shown in FIG. 14A, a support 200 can be introduced into the canal using syringe 202 and plunger 204. Syringe 202 has distal end 206 that can be at least partially inserted into or placed adjacent to an opening in the canal. Force in a distal direction is applied to plunger 204, thereby pushing support 200 into the canal. Referring to FIGS. 14B-C, distal end 208 of guide element 210 can be at least partially introduced into the canal. Guide element 210 can be a guide wire. Guide element 210 can be extended circumferentially along the canal to aid in positioning the support. Support 212 comprises central bore 218 capable of accommodating guide element 210 such that support 212 can be threaded onto guide element 210 and slidably positioned along the guide element. Once distal end 209 of support 212 is threaded onto guide element 210, support 212 can be pushed in a distal direction along guide element 210 to insert support 212 into the canal. In some variations, support 212 can remain threaded onto guide element 210, and guide element 210 can remain in the canal. In other variations, support 212 can be slid off distal end 208 of guide element 210, and the guide element can be pulled in a proximal direction for removal. Referring to FIGS. 14C-D, syringe 202 with plunger 204 can be used in combination with a guide element 210. In this variation, distal end 208 of guide element 210 is inserted at least partially into Schlemm's canal. Guide element 210 can be extended circumferentially along the canal to aid in positioning the support. Support 212 has central bore 218 capable of accommodating guide element 210. Proximal end 211 of guide element 210 is inserted into bore 218. Plunger 204 is depressed in a distal direction to push support 212 into the canal and slide support 212 along element 210. Guide element 210 can remain in the canal or be removed following insertion of the support. Supports 200, 212 must be sufficiently resilient to withstand force encountered as they are pushed into the canal.


In some variations, a positioning device may be used with the introducer to position or adjust the support within the canal. A positioning device can include a rod, grippers, a clamp, a hook, or the like. In other variations, a device or system capable of dilating the canal to facilitate insertion of a support may be included in the kits, e.g., a syringe or other device capable of injecting fluid into the canal.


In some variations, the kits contain at least two supports. Multiple supports can be implanted within one eye or within multiple eyes. If the kits contain multiple supports, the kits may also contain multiple introducers. Alternatively, the same introducer may be used for implantation of multiple supports, especially if the multiple supports are being delivered to a single eye. If multiple supports are to be delivered with the same introducer, then the multiple supports can be preloaded into the introducer for sterility. If more than one support is included in a kit, the supports may be of different shapes, sizes, lengths, or materials. If the kits contain more than one support to be implanted into a single eye, the supports can be connected together.


The kits can comprise an active agent, such as a pharmaceutical agent. The active agent may be included as an integral part of the support, or may be supplied in kits for application to the support or to the eye during or after implantation. Examples of active agents that may be supplied as part of the kits include prostaglandins, prostaglandin analogs, beta blockers, alpha-2 agonists, calcium channel blockers, carbonic anhydrase inhibitors, growth factors, such as tissue growth factors or vascular endothelial growth factors, anti-metabolites, chemotherapeutic agents such as mitomycin-C,5-fluorouracil, steroids, antagonists of growth factors, such as antagonists of vascular endothelial growth factor, and combinations thereof.


The kits may contain a fixation device for attaching a support to tissue. Such a fixation device can include sutures, hooks, barbs, clips, adhesives, and combinations thereof. In addition, the kits may include a system for visually enhancing the support to facilitate viewing, positioning, and monitoring of a support. A system for visually enhancing the support can include a light source, a transmission or absorption filter, a mirror, a composition comprising a chromophore capable of fluorescing or phosphorescing that can be applied to the support, or any combination thereof. Chromophores can assist a clinician in verifying the position of the support postoperatively using a gonioscope, for example. The light source is capable of exciting a chromophore contained within or on the support such that the chromophore emits fluorescence or phosphorescence. The emission is preferably within the wavelength range of about 300 nm to about 800 nm. A suitable light source for such a system can comprise a laser, a light emitting diode, or a lamp. In some instances, transmission or absorption filters may be used to further select the wavelength range of the excitation source or view or detect emission from chromophores. One or more mirrors may be used to direct a light source or emitted light, or to view the support.


Methods

Methods for reducing intraocular pressure are also provided. In general, the methods comprise inserting a support circumferentially within Schlemm's canal, such that the support maintains the patency of at least a portion of the canal. The support occupies at least a portion of a central core of Schlemm's canal and does not substantially interfere with transmural flow across Schlemm's canal.


The methods can comprise inserting a support circumferentially into Schlemm's canal using an introducer and/or a positioning device. The introducer can include a cannula and a tubular or hollow pusher rod. The support can be installed in the lumen of the cannula at its distal end and the pusher rod can be inserted into the lumen of the cannula at its proximal end and extended distally to push the support into position in the canal. In some instances, the cannula and/or the pusher rod may be flexible and small enough in diameter to at least partially extend circumferentially around the canal. In some variations of the methods, a positioning device can be used in addition to an introducer. The positioning device can comprise a second rod, a gripper, a hook, a clamp, or the like. In some variations, the methods include illuminating a support with a light source to causes the support to fluoresce or phosphoresce, thus aiding the visual appearance of the support. The illuminating of the support can occur during or after implantation to inspect the support, e.g., to monitor its position, condition, or performance.


In some instances, the methods will also comprise dilating Schlemm's canal prior to insertion of the support. Dilation of the canal can be accomplished by injecting fluid into the canal. For example, a high viscosity fluid such as sodium hyaluronate, or other dilating fluids known in the art, can be used to dilate the canal.


The methods may include implanting more than one support into an eye. In some variations, the methods will include implantation of two or more supports circumferentially adjacent to each other within the canal, and in other variations, the methods will include implantation of supports circumferentially opposed to each other within the canal, e.g., two supports centered about 180° apart around the circumference of Schlemm's canal. Some variations of the methods can comprise connecting together multiple supports in a single eye.


In some variations, the methods can include anchoring the support to tissue surrounding Schlemm's canal. Anchoring the support to tissue can be accomplished in a variety of ways, e.g., by suturing, application of adhesives, installation of hooks, clips, or the like, or combinations thereof. In other variations, the methods can comprise selecting the size of the support such that the support fits securely into the canal by a friction fit. Examples of arcuate supports that can be implanted with a friction fit are illustrated in FIGS. 11A-C.


The methods described here can also include altering the support using electromagnetic radiation. For example, a support can include regions capable of preferentially absorbing a certain wavelength range. When electromagnetic radiation of the appropriate wavelength range with sufficient energy is incident upon the support, material in the preferentially absorbing regions will melt or ablate, resulting in perforations or indentations in the support at those regions. For example, a pulsed titanium sapphire laser emitting at about 750 nm to about 800 nm incident on gold can cause the gold to melt or ablate. The alteration of the support using electromagnetic radiation can occur before or after implantation of a support. For example, fenestrations can be created or enlarged in a support after the support has remained in an eye for a period of time to enhance drainage.


While the inventive devices, kits and methods have been described in some detail by way of illustration, such illustration is for purposes of clarity of understanding only. It will be readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims. For example, it is envisioned that the devices, kits and methods can be applied to nonhuman eyes to reduce intraocular pressure, e.g., in dogs, cats, primates, or horses.

Claims
  • 1. A method for treating a condition of the eye, comprising: delivering a high viscosity fluid into Schlemm's canal;inserting a distal end of an introducer into Schlemm's canal; andplacing a support in Schlemm's canal by operating the introducer.
  • 2. The method of claim 1, wherein the introducer comprises a pusher rod.
  • 3. The method of claim 2, wherein the support is advanced by operating the pusher rod from a proximal end of the introducer.
  • 4. The method of claim 1, further comprising anchoring the support to tissue surrounding Schlemm's canal.
  • 5. The method of claim 1, further comprising using a gonioscope.
  • 6. The method of claim 1, further comprising adjusting the position of the support using a positioning device.
  • 7. The method of claim 1, wherein the support extends about a quarter or less than a quarter of the circumference of Schlemm's canal after placement.
  • 8. The method of claim 1, wherein at least a portion of the support extends out of Schlemm's canal after placement.
  • 9. The method of claim 1, wherein the support does not substantially interfere with longitudinal flow along the canal after placement.
  • 10. The method of claim 1, wherein the support enhances transmural flow across the wall of the canal after placement.
  • 11. The method of claim 1, wherein the support extends circumferentially along Schlemm's canal after placement.
  • 12. The method of claim 1, wherein when the support is disposed within a cylindrical section of the lumen of Schlemm's canal having an internal wall surface area C, the support contacts less than 30% of C.
  • 13. The method of claim 1, wherein when the support is disposed within a cylindrical section of the lumen of Schlemm's canal having an internal wall surface area C, the support contacts less than 10% of C.
  • 14. The method of claim 1, wherein the high viscosity fluid is sodium hyaluronate.
  • 15. The method of claim 1, wherein at least a portion of the support is made from a shape memory material.
  • 16. The method of claim 15, wherein the shape memory material comprises a shape memory alloy.
  • 17. The method of claim 16, wherein the shape memory alloy comprises a nickel titanium alloy.
  • 18. The method of claim 1, wherein the support is flexible.
  • 19. The method of claim 1, wherein the support comprises a central bore.
  • 20. The method of claim 1, wherein the support comprises at least one fenestration.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/340,911, filed on Nov. 1, 2016, which is a continuation of U.S. patent application Ser. No. 13/445,816, filed on Apr. 12, 2012 (now U.S. Pat. No. 9,486,361), which is a continuation of U.S. patent application Ser. No. 12/695,053, filed on Jan. 27, 2010 (now U.S. Pat. No. 8,287,482), which is a continuation of U.S. patent application Ser. No. 11/475,523, filed on Jun. 26, 2006 (now U.S. Pat. No. 7,909,789), the disclosures of which are hereby incorporated by reference in their entirety.

US Referenced Citations (356)
Number Name Date Kind
3159161 Ness Dec 1964 A
4068664 Sharp et al. Jan 1978 A
4457757 Molteno Jul 1984 A
1501274 Skjaerpe Feb 1985 A
4553545 Maass et al. Nov 1985 A
4719825 LaHaye et al. Jan 1988 A
4863457 Lee Sep 1989 A
1936825 Ungerleider Jun 1990 A
4957505 McDonald Sep 1990 A
5092837 Ritch et al. Mar 1992 A
5180362 Worst Jan 1993 A
5284476 Koch Feb 1994 A
5358473 Mitchell Oct 1994 A
5360399 Stegmann Nov 1994 A
5368572 Shirota Nov 1994 A
5486165 Stegmann Jan 1996 A
5540657 Kurjan et al. Jul 1996 A
5558634 Mitchell Sep 1996 A
5569197 Helmus et al. Oct 1996 A
5626558 Suson May 1997 A
5639278 Dereume et al. Jun 1997 A
5792099 DeCamp et al. Aug 1998 A
5792103 Schwartz et al. Aug 1998 A
5868697 Richter et al. Feb 1999 A
6036678 Giungo Mar 2000 A
6050970 Baerveldt Apr 2000 A
6050999 Paraschac et al. Apr 2000 A
6299603 Hecker et al. Oct 2001 B1
6309375 Glines et al. Oct 2001 B1
6375642 Grieshaber et al. Apr 2002 B1
6450984 Lynch et al. Sep 2002 B1
6491670 Toth et al. Dec 2002 B1
6494857 Neuhann Dec 2002 B1
6508779 Suson Jan 2003 B1
6524275 Lynch et al. Feb 2003 B1
6533768 Hill Mar 2003 B1
6616996 Keith et al. Sep 2003 B1
6626858 Lynch et al. Sep 2003 B2
6638239 Bergheim et al. Oct 2003 B1
6666841 Gharib et al. Dec 2003 B2
6726676 Stegmann et al. Apr 2004 B2
6730056 Ghaem et al. May 2004 B1
6736791 Tu et al. May 2004 B1
6780164 Bergheim et al. Aug 2004 B2
6783544 Lynch et al. Aug 2004 B2
6840952 Saker et al. Jan 2005 B2
6843792 Nishtala et al. Jan 2005 B2
6893415 Madsen et al. May 2005 B2
6955656 Bergheim et al. Oct 2005 B2
6962573 Wilcox Nov 2005 B1
7094225 Tu et al. Aug 2006 B2
7135009 Tu et al. Nov 2006 B2
7186232 Smedley et al. Mar 2007 B1
7192412 Zhou et al. Mar 2007 B1
7207980 Christian et al. Apr 2007 B2
7273475 Tu et al. Sep 2007 B2
7297130 Bergheim et al. Nov 2007 B2
7331984 Tu et al. Feb 2008 B2
7488303 Haffner et al. Feb 2009 B1
7588597 Frid Sep 2009 B2
7713228 Robin May 2010 B2
7740604 Schieber et al. Jun 2010 B2
7806847 Wilcox Oct 2010 B2
7850637 Lynch et al. Dec 2010 B2
7867205 Bergheim et al. Jan 2011 B2
7909789 Badawi Mar 2011 B2
7951155 Smedley et al. May 2011 B2
7967772 McKenzie et al. Jun 2011 B2
8034105 Stegmann et al. Oct 2011 B2
8075511 Tu et al. Dec 2011 B2
8109896 Nissan et al. Feb 2012 B2
8123729 Yamamoto et al. Feb 2012 B2
8133208 Hetherington Mar 2012 B2
8137307 Tennican et al. Mar 2012 B2
8152752 Lynch et al. Apr 2012 B2
8172899 Silvestrini et al. May 2012 B2
8267882 Euteneuer et al. Sep 2012 B2
8273050 Bergheim et al. Sep 2012 B2
8282592 Schieber et al. Oct 2012 B2
8287482 Badawi et al. Oct 2012 B2
8333742 Bergheim et al. Dec 2012 B2
8337509 Schieber et al. Dec 2012 B2
8348924 Christian et al. Jan 2013 B2
8366653 Shareef et al. Feb 2013 B2
8372026 Schieber et al. Feb 2013 B2
8388568 Lynch et al. Mar 2013 B2
8403920 Lind et al. Mar 2013 B2
8414518 Schieber et al. Apr 2013 B2
8414636 Nabulsi et al. Apr 2013 B2
8425449 Wardle et al. Apr 2013 B2
8425450 Wilcox Apr 2013 B2
8439972 Badawi et al. May 2013 B2
8444589 Silvestrini May 2013 B2
8491549 Conston et al. Jul 2013 B2
8512321 Baerveldt et al. Aug 2013 B2
8512404 Frion et al. Aug 2013 B2
8529622 Badawi et al. Sep 2013 B2
8540659 Berlin Sep 2013 B2
8540681 Hetherington Sep 2013 B2
8540761 Rabkin et al. Sep 2013 B2
8545431 Rickard Oct 2013 B2
8568391 Kearns et al. Oct 2013 B2
8617094 Smedley et al. Dec 2013 B2
8657776 Wardle et al. Feb 2014 B2
8663150 Wardle et al. Mar 2014 B2
8715266 Bos May 2014 B2
8734377 Schieber et al. May 2014 B2
8747299 Grieshaber Jun 2014 B2
8771217 Lynch et al. Jul 2014 B2
8801648 Bergheim et al. Aug 2014 B2
8808222 Schieber et al. Aug 2014 B2
8827990 Van Valen et al. Sep 2014 B2
8852137 Horvath et al. Oct 2014 B2
8876898 Badawi et al. Nov 2014 B2
8888734 Nissan et al. Nov 2014 B2
8894603 Badawi et al. Nov 2014 B2
8926546 Wilcox Jan 2015 B2
8961447 Schieber et al. Feb 2015 B2
9039650 Schieber et al. May 2015 B2
9044301 Pinchuk et al. Jun 2015 B1
9050169 Schieber et al. Jun 2015 B2
9066750 Wardle et al. Jun 2015 B2
9066783 Euteneuer et al. Jun 2015 B2
9095412 Badawi et al. Aug 2015 B2
9107729 Sorensen et al. Aug 2015 B2
9125723 Horvath et al. Sep 2015 B2
9155655 Schieber et al. Oct 2015 B2
9192516 Horvath et al. Nov 2015 B2
9211213 Wardle et al. Dec 2015 B2
9216109 Badawi et al. Dec 2015 B2
9220632 Smedley et al. Dec 2015 B2
9226850 Baerveldt et al. Jan 2016 B2
9226852 Schieber et al. Jan 2016 B2
9301875 Tu et al. Apr 2016 B2
9326891 Horvath et al. May 2016 B2
9339514 Bos et al. May 2016 B2
9351874 Schieber et al. May 2016 B2
9358155 Sorensen et al. Jun 2016 B2
9358156 Wardle et al. Jun 2016 B2
9370443 Badawi et al. Jun 2016 B2
9381111 Hickingbotham et al. Jul 2016 B2
9402767 Schieber et al. Aug 2016 B2
9486361 Badawi et al. Nov 2016 B2
9492319 Grieshaber et al. Nov 2016 B2
9492320 Lynch et al. Nov 2016 B2
9510973 Wardle Dec 2016 B2
9855167 Badawi et al. Jan 2018 B2
9889258 Bengtsson et al. Feb 2018 B2
9895258 Badawi et al. Feb 2018 B2
10154924 Clauson et al. Dec 2018 B2
10179066 Badawi et al. Jan 2019 B2
10299958 Badawi et al. May 2019 B2
10314742 Badawi et al. Jun 2019 B2
10398597 Badawi Sep 2019 B2
10406030 Badawi et al. Sep 2019 B2
10857027 Badawi et al. Dec 2020 B2
10888453 Badawi et al. Jan 2021 B2
10905591 Ianchulev Feb 2021 B1
11090188 Badawi et al. Aug 2021 B2
11116660 Badawi et al. Sep 2021 B2
11166847 Badawi et al. Nov 2021 B2
11259961 Ianchulev Mar 2022 B2
11344447 Badawi et al. May 2022 B2
11389327 Badawi et al. Jul 2022 B2
11389328 Badawi et al. Jul 2022 B2
11419762 Ianchulev Aug 2022 B2
11471324 Badawi et al. Oct 2022 B2
11504270 Badawi et al. Nov 2022 B1
11617679 Badawi et al. Apr 2023 B2
20010014788 Morris Aug 2001 A1
20020013546 Grieshaber et al. Jan 2002 A1
20020013572 Berlin Jan 2002 A1
20020055753 Silvestrini May 2002 A1
20020072673 Yamamoto et al. Jun 2002 A1
20020133168 Smedley et al. Sep 2002 A1
20020143284 Tu et al. Oct 2002 A1
20020165478 Gharib et al. Nov 2002 A1
20030060447 Karakelle et al. Mar 2003 A1
20030060752 Bergheim et al. Mar 2003 A1
20030060873 Gertner et al. Mar 2003 A1
20030120200 Bergheim et al. Jun 2003 A1
20030181848 Bergheim et al. Sep 2003 A1
20030229303 Haffner et al. Dec 2003 A1
20030236483 Ren Dec 2003 A1
20030236484 Lynch et al. Dec 2003 A1
20040044310 Suzuki Mar 2004 A1
20040102719 Keith et al. May 2004 A1
20040102729 Haffner et al. May 2004 A1
20040147870 Burns et al. Jul 2004 A1
20040193095 Shadduck Sep 2004 A1
20040193262 Shadduck Sep 2004 A1
20040210181 Vass et al. Oct 2004 A1
20040254519 Tu et al. Dec 2004 A1
20040254520 Porteous Dec 2004 A1
20040254521 Simon Dec 2004 A1
20040260228 Lynch et al. Dec 2004 A1
20050038334 Lynch et al. Feb 2005 A1
20050055082 Ben Muvhar et al. Mar 2005 A1
20050090807 Lynch et al. Apr 2005 A1
20050101967 Weber et al. May 2005 A1
20050125003 Pinchuk et al. Jun 2005 A1
20050165363 Judson et al. Jul 2005 A1
20050171507 Christian Aug 2005 A1
20050192527 Gharib et al. Sep 2005 A1
20050209549 Bergheim et al. Sep 2005 A1
20050250788 Tu et al. Nov 2005 A1
20050266047 Tu et al. Dec 2005 A1
20050267555 Marnfeldt et al. Dec 2005 A1
20050277864 Haffner et al. Dec 2005 A1
20050288619 Gharib et al. Dec 2005 A1
20060032507 Tu Feb 2006 A1
20060034891 Lawin et al. Feb 2006 A1
20060036207 Koonmen et al. Feb 2006 A1
20060069340 Simon Mar 2006 A1
20060074375 Bergheim et al. Apr 2006 A1
20060084907 Bergheim et al. Apr 2006 A1
20060116626 Smedley et al. Jun 2006 A1
20060149194 Conston Jul 2006 A1
20060155300 Stamper et al. Jul 2006 A1
20060173077 Cagle Aug 2006 A1
20060173397 Tu et al. Aug 2006 A1
20060173446 Dacquay et al. Aug 2006 A1
20060195055 Bergheim et al. Aug 2006 A1
20060195056 Bergheim et al. Aug 2006 A1
20060195187 Stegmann et al. Aug 2006 A1
20060200113 Haffner et al. Sep 2006 A1
20060217741 Ghannoum Sep 2006 A1
20060241580 Mittelstein et al. Oct 2006 A1
20070073275 Conston et al. Mar 2007 A1
20070106236 Coroneo May 2007 A1
20070191863 De Juan, Jr. et al. Aug 2007 A1
20070260173 Boukhny et al. Nov 2007 A1
20070276420 Sorensen et al. Nov 2007 A1
20080004596 Yun et al. Jan 2008 A1
20080058704 Hee et al. Mar 2008 A1
20080058760 Agerup Mar 2008 A1
20080082078 Berlin Apr 2008 A1
20080108934 Berlin May 2008 A1
20080300574 Belson et al. Dec 2008 A1
20090036819 Tu et al. Feb 2009 A1
20090036827 Cazzini Feb 2009 A1
20090043321 Conston et al. Feb 2009 A1
20090082860 Schieber et al. Mar 2009 A1
20090082862 Schieber et al. Mar 2009 A1
20090082863 Schieber et al. Mar 2009 A1
20090132040 Frion et al. May 2009 A1
20090227934 Euteneuer et al. Sep 2009 A1
20090247955 Yamamoto et al. Oct 2009 A1
20090287143 Line Nov 2009 A1
20090287233 Huculak Nov 2009 A1
20100019177 Luckevich Jan 2010 A1
20100087774 Haffner et al. Apr 2010 A1
20100121248 Yu et al. May 2010 A1
20100121342 Schieber et al. May 2010 A1
20100173866 Hee et al. Jul 2010 A1
20100179652 Yamamoto et al. Jul 2010 A1
20100222802 Gillespie Sep 2010 A1
20100241046 Pinchuk et al. Sep 2010 A1
20100262174 Sretavan et al. Oct 2010 A1
20110009874 Wardle et al. Jan 2011 A1
20110009958 Wardle et al. Jan 2011 A1
20110098809 Wardle et al. Apr 2011 A1
20110224597 Stegmann et al. Sep 2011 A1
20110238009 Meron et al. Sep 2011 A1
20110238075 Clauson et al. Sep 2011 A1
20110306915 De Juan, Jr. et al. Dec 2011 A1
20120010702 Stegmann et al. Jan 2012 A1
20120123315 Horvath et al. May 2012 A1
20120123434 Grabner et al. May 2012 A1
20120136306 Bartha May 2012 A1
20120165720 Horvath et al. Jun 2012 A1
20120191064 Conston et al. Jul 2012 A1
20120197175 Horvath et al. Aug 2012 A1
20120203160 Kahook et al. Aug 2012 A1
20120220917 Silvestrini et al. Aug 2012 A1
20120310072 Grieshaber Dec 2012 A1
20120310137 Silvestrini Dec 2012 A1
20120325704 Kerns et al. Dec 2012 A1
20130041346 Alon Feb 2013 A1
20130150959 Schieber et al. Jun 2013 A1
20130158462 Wardle et al. Jun 2013 A1
20130245600 Yamamoto et al. Sep 2013 A1
20130274655 Jennings et al. Oct 2013 A1
20140018771 Shekalim Jan 2014 A1
20140066833 Yaron et al. Mar 2014 A1
20140081194 Burns et al. Mar 2014 A1
20140121584 Wardle et al. May 2014 A1
20140128847 Lopez May 2014 A1
20140135916 Clauson et al. May 2014 A1
20140163448 Lind et al. Jun 2014 A1
20140171852 Khor Jun 2014 A1
20140194916 Ichikawa Jul 2014 A1
20140213958 Clauson et al. Jul 2014 A1
20140236066 Horvath et al. Aug 2014 A1
20140276332 Crimaldi et al. Sep 2014 A1
20140288485 Berlin Sep 2014 A1
20140309599 Schaller Oct 2014 A1
20140364791 Stegmann et al. Dec 2014 A1
20150005623 Grover et al. Jan 2015 A1
20150011926 Reitsamer et al. Jan 2015 A1
20150051699 Badawi et al. Feb 2015 A1
20150065940 Rangel-Friedman et al. Mar 2015 A1
20150080783 Berlin Mar 2015 A1
20150112372 Perez Grossmann Apr 2015 A1
20150119787 Wardle et al. Apr 2015 A1
20150125328 Bourne et al. May 2015 A1
20150133946 Horvath et al. May 2015 A1
20150148615 Brennan et al. May 2015 A1
20150216729 Doci Aug 2015 A1
20150223981 Smedley et al. Aug 2015 A1
20150223983 Schieber et al. Aug 2015 A1
20150223984 Schieber et al. Aug 2015 A1
20150250649 Euteneuer et al. Sep 2015 A1
20150257932 Pinchuk et al. Sep 2015 A1
20150282982 Schieber et al. Oct 2015 A1
20150313758 Wilcox Nov 2015 A1
20150320596 Gifford, III et al. Nov 2015 A1
20150374545 Horvath et al. Dec 2015 A1
20160022486 Clauson et al. Jan 2016 A1
20160051408 Baerveldt et al. Feb 2016 A1
20160095985 Novak Apr 2016 A1
20160100980 Badawi et al. Apr 2016 A1
20160106589 Mittelstein et al. Apr 2016 A1
20160135994 Romoda et al. May 2016 A1
20160143778 Aljuri et al. May 2016 A1
20160151204 Haffner et al. Jun 2016 A1
20160158453 Oakley et al. Jun 2016 A1
20160220417 Schieber et al. Aug 2016 A1
20160220418 Sorensen et al. Aug 2016 A1
20160256317 Horvath et al. Sep 2016 A1
20160256323 Horvath et al. Sep 2016 A1
20160287438 Badawi et al. Oct 2016 A1
20160302965 Erickson et al. Oct 2016 A1
20160331588 Ambati et al. Nov 2016 A1
20160346006 Hickengbotham et al. Dec 2016 A1
20160354248 Kahook Dec 2016 A1
20170202707 Badawi et al. Jul 2017 A1
20170258507 Hetherington Sep 2017 A1
20180243131 Erickson et al. Aug 2018 A1
20180263817 Roeber et al. Sep 2018 A1
20180271699 Badawi et al. Sep 2018 A1
20190142632 Badawi et al. May 2019 A1
20190314200 Badawi et al. Oct 2019 A1
20200038243 Badawi et al. Feb 2020 A1
20200129333 Badawi et al. Apr 2020 A1
20210236333 Badawi et al. Aug 2021 A1
20210386584 Badawi et al. Dec 2021 A1
20220104967 Badawi et al. Apr 2022 A1
20220168146 Badawi et al. Jun 2022 A1
20220280339 Badawi et al. Sep 2022 A1
20220280340 Badawi et al. Sep 2022 A1
20220354695 Badawi et al. Nov 2022 A1
20220378612 Badawi et al. Dec 2022 A1
20230181355 Badawi et al. Jun 2023 A1
20230233371 Badawi et al. Jul 2023 A1
20230233372 Badawi et al. Jul 2023 A1
Foreign Referenced Citations (43)
Number Date Country
2244646 Feb 1999 CA
2778452 Apr 2011 CA
1678407 Oct 2005 CN
101505830 Aug 2009 CN
201824103 May 2011 CN
102202706 Sep 2011 CN
202400240 Aug 2012 CN
2 830 553 Dec 2017 EP
03-168154 Jul 1991 JP
2002-541976 Dec 2002 JP
2003-180730 Jul 2003 JP
2005-510317 Apr 2005 JP
2005-538809 Dec 2005 JP
2007-527251 Sep 2007 JP
2012-527318 Nov 2012 JP
2013-512707 Apr 2013 JP
2014-036867 Feb 2014 JP
2014-533600 Dec 2014 JP
WO-0064391 Nov 2000 WO
WO-0064393 Nov 2000 WO
WO-0197727 Dec 2001 WO
WO-0236052 May 2002 WO
WO-03045582 Jun 2003 WO
WO-2004026361 Apr 2004 WO
WO-2004069664 Aug 2004 WO
WO-2005016418 Feb 2005 WO
WO-2005105197 Nov 2005 WO
WO-2005107664 Nov 2005 WO
WO-2005117752 Dec 2005 WO
WO-2006066103 Jun 2006 WO
WO-2008002377 Jan 2008 WO
WO-2009042596 Apr 2009 WO
WO-2009067369 May 2009 WO
WO-2009111645 Sep 2009 WO
WO-2010065970 Jun 2010 WO
WO-2011006078 Jan 2011 WO
WO-2011006113 Jan 2011 WO
WO-2011050360 Apr 2011 WO
WO-2011097408 Aug 2011 WO
WO-2011106781 Sep 2011 WO
WO-2013141898 Sep 2013 WO
WO-2016042162 Mar 2016 WO
WO-2016159999 Oct 2016 WO
Non-Patent Literature Citations (187)
Entry
Boyle, E.L. (Feb. 1, 2006). “New Glaucoma Devices Take Different Approaches to IOP Lowering,” Ocular Surgery News U.S. Edition, located at <http://www.osnsupersite.com/view.aspx?rid=12436>, last visited on Apr. 23, 2012, 4 pages, revisited on Apr. 19, 2016, 5 pages.
Corrected Notice of Allowability dated Nov. 23, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 2 pages.
Corrected Notice of Allowability dated Dec. 12, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 2 pages.
Corrected Notice of Allowability dated Feb. 21, 2019, for U.S. Appl. No. 14/675,580, filed Mar. 31, 2015, 6 pages.
Corrected Notice of Allowability dated Apr. 3, 2019, for U.S. Appl. No. 14/675,580, filed Mar. 31, 2015, 3 pages.
Extended European Search Report dated Apr. 22, 2015, for EP Patent Application No. 11 740 372.5, filed Feb. 3, 2011, six pages.
Extended European Search Report dated Jun. 9, 2016, for European Patent Application No. 16 155 079.3, filed on May 31, 2007, 7 pages.
Extended European Search Report dated May 17, 2011, for European Patent Application No. 11 162 487.0, filed on May 31, 2007, 6 pages.
Extended European Search Report dated Mar. 24, 2016, for European Patent Application No. 12 871 982.0, filed on Oct. 4, 2012, 7 pages.
Extended European Search Report dated Nov. 20, 2018, for European Patent Application No. 15 888 007.0, filed on Mar. 31, 2015, 9 pages.
Final Office Action dated Nov. 1, 2010, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 12 pages.
Final Office Action dated Jul. 19, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 6 pages.
Final Office Action dated Feb. 1, 2013, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 6 pages.
Final Office Action dated Sep. 15, 2014, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 13 pages.
Final Office Action dated Sep. 20, 2013, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 16 pages.
Final Office Action dated Nov. 12, 2013, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 8 pages.
Final Office Action dated Jan. 8, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 8 pages.
Final Office Action dated Sep. 3, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 8 pages.
Final Office Action dated Apr. 23, 2015, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 8 pages.
Final Office Action dated Aug. 19, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 6 pages.
Final Office Action dated Mar. 9, 2016, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 11 pages.
Final Office Action dated Oct. 3, 2016, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 27 pages.
Final Office Action dated May 18, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 14 pages.
Final Office Action dated Jan. 29, 2018, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 19 pages.
Final Office Action dated Apr. 6, 2018, for U.S. Appl. No. 15/683,652, filed Aug. 22, 2017, 11 pages.
Final Office Action dated Jun. 1, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 6 pages.
Final Office Action dated Oct. 19, 2018, for U.S. Appl. No. 15/683,652, filed Aug. 22, 2017, 8 pages.
Final Office Action dated Apr. 19, 2019, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 12 pages.
International Search Report dated Nov. 30, 2007, for PCT Application No. PCT/US2007/013038, filed on May 31, 2007, 4 pages.
International Search Report dated Apr. 5, 2011, for PCT Application No. PCT/US2011/023643, filed on Feb. 3, 2011, 2 pages.
International Search Report dated Feb. 1, 2013 for PCT Application No. PCT/US2012/058751, filed on Oct. 4, 2012, 4 pages.
International Search Report dated Sep. 14, 2015, for PCT Application No. PCT/US2015/023720, filed on Mar. 31, 2015, 5 pages.
Non-Final Office Action dated May 17, 2010, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 10 pages.
Non-Final Office Action dated Jan. 26, 2012, for U.S. Appl. No. 12/695,053, filed Jan. 27, 2010, 10 pages.
Non-Final Office Action dated Mar. 15, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 4 pages.
Non-Final Office Action dated May 11, 2012, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 5 pages.
Non-Final Office Action dated Nov. 9, 2012, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 5 pages.
Non-Final Office Action dated Apr. 24, 2013, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 13 pages.
Non-Final Office Action dated Jun. 12, 2013, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 8 pages.
Non-Final Office Action dated Sep. 9, 2013, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages.
Non-Final Office Action dated Feb. 7, 2014, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 12 pages.
Non-Final Office Action dated Feb. 24, 2014, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 12 pages.
Non-Final Office Action dated May 15, 2014, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages.
Non-Final Office Action dated Nov. 28, 2014, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 7 pages.
Non-Final Office Action dated Jan. 14, 2015, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 10 pages.
Non-Final Office Action dated Feb. 4, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 6 pages.
Non-Final Office Action dated Feb. 23, 2015, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 17 pages.
Non-Final Office Action dated Jul. 10, 2015, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 16 pages.
Non-Final Office Action dated Oct. 7, 2015, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 5 pages.
Non-Final Office Action dated Nov. 3, 2015, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 7 pages.
Non-Final Office Action dated Dec. 14, 2015, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 7 pages.
Non-Final Office Action dated Jun. 7, 2016, for U.S. Appl. No. 14/527,292, filed Oct. 29, 2014, 5 pages.
Non-Final Office Action dated Feb. 25, 2016, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 19 pages.
Non-Final Office Action dated Jan. 18, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 13 pages.
Non-Final Office Action dated Mar. 22, 2017, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 31 pages.
Non-Final Office Action dated Aug. 28, 2017, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 6 pages.
Non-Final Office Action dated Nov. 7, 2017, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 14 pages.
Non-Final Office Action dated Dec. 15, 2017, for U.S. Appl. No. 15/343,147, filed Nov. 3, 2016, 12 pages.
Non-Final Office Action dated Apr. 4, 2018, for U.S. Appl. No. 14/675,580, filed Mar. 31, 2015, 10 pages.
Non-Final Office Action dated Aug. 9, 2018, for U.S. Appl. No. 15/182,165, filed Jun. 14, 2016, 9 pages.
Non-Final Office Action dated Aug. 29, 2018, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 11 pages.
Non-Final Office Action dated Sep. 20, 2018, for U.S. Appl. No. 15/340,911, filed Nov. 1, 2016, 7 pages.
Non-Final Office Action dated Oct. 7, 2019, for U.S. Appl. No. 15/854,126, filed Dec. 26, 2017, 13 pages.
Non-Final Office Action dated Nov. 25, 2019, for U.S. Appl. No. 16/189,882, filed Nov. 13, 2018, 12 pages.
Notice of Allowance dated Feb. 2, 2011, for U.S. Appl. No. 11/475,523, filed Jun. 26, 2006, 6 pages.
Notice of Allowance dated Jun. 11, 2012, for U.S. Appl. No. 12/695,053, filed Jan. 27, 2010, 7 pages.
Notice of Allowance dated Apr. 2, 2013, for U.S. Appl. No. 13/245,811, filed Sep. 26, 2011, 6 pages.
Notice of Allowance dated May 10, 2013, for U.S. Appl. No. 13/020,706, filed Feb. 3, 2011, 8 pages.
Notice of Allowance dated Jul. 7, 2014, for U.S. Appl. No. 14/012,963, filed Aug. 28, 2013, 6 pages.
Notice of Allowance dated Jul. 23, 2014, for U.S. Appl. No. 13/644,780, filed Oct. 4, 2012, 8 pages.
Notice of Allowance dated Mar. 30, 2015, for U.S. Appl. No. 13/644,748, filed Oct. 4, 2012, 5 pages.
Notice of Allowance dated Aug. 10, 2015, for U.S. Appl. No. 13/644,758, filed Oct. 4, 2012, 7 pages.
Notice of Allowance dated Mar. 1, 2016, for U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 7 pages.
Corrected Notice of Allowability dated Apr. 25, 2016, U.S. Appl. No. 13/025,112, filed Feb. 10, 2011, 2 pages.
Notice of Allowance dated Jul. 13, 2016, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 7 pages.
Corrected Notice of Allowability dated Sep. 1, 2016, for U.S. Appl. No. 13/445,816, filed Apr. 12, 2012, 2 pages.
Notice of Allowance dated Oct. 25, 2017, for U.S. Appl. No. 13/644,769, filed Oct. 4, 2012, 8 pages.
Notice of Allowance dated Nov. 21, 2017, for U.S. Appl. No. 14/539,648, filed Nov. 12, 2014, 10 pages.
Notice of Allowance dated Aug. 31, 2018, for U.S. Appl. No. 14/816,822, filed Aug. 3, 2015, 7 pages.
Notice of Allowance dated Jan. 9, 2019, for U.S. Appl. No. 14/675,580, filed Mar. 31, 2015, 9 pages.
Notice of Allowance dated Feb. 6, 2019, for U.S. Appl. No. 15/182,165, filed Jun. 14, 2016, 8 pages.
Notice of Allowance dated Apr. 15, 2019, for U.S. Appl. No. 15/683,652, filed Aug. 22, 2017, 5 pages.
Notice of Allowance dated Apr. 23, 2019, for U.S. Appl. No. 15/340,911, filed Nov. 1, 2016, 5 pages.
Written Opinion dated Nov. 30, 2007, for PCT Application No. PCT/US2007/013038, filed on May 31, 2007, 6 pages.
Written Opinion dated Apr. 5, 2011, for PCT Application No. PCT/US2011/023643, filed on Feb. 3, 2011, 5 pages.
Written Opinion dated Feb. 1, 2013 for PCT Application No. PCT/US2012/058751, filed on Oct. 4, 2012, 6 pages.
Written Opinion dated Sep. 14, 2015 for PCT Application No. PCT/US15/23720, filed on Mar. 31, 2015, 8 pages.
Final Office Action dated Jun. 9, 2020, for U.S. Appl. No. 15/854,126, filed Dec. 26, 2017, 9 pages.
Final Office Action dated Jun. 9, 2020, for U.S. Appl. No. 16/189,882, filed Nov. 13, 2018, 12 pages.
Bahler, C.K. et al. (2004). “Trabecular bypass stents decrease intraocular pressure in cultured human anterior segments,” Am. J. Ophthalmol. 138:988-994.
Butany, J. et al. (2005). “Coronary artery stents; identification and evaluation,” J. Clin. Pathol. 58:795-804.
ClinicalTrials.Gov (2006). A study of the trabecular micro-bypass stent in combnination with cataract surgery in subjects with open angle glaucoma, NCT00323284, 6 total pages.
Colombo, A. et al. (2002). “Selection of coronary stents,” J. Am. Coll. Cardiol. 40:1021-1033.
Corrected Notice of Allowability dated Oct. 12, 2021, for U.S. Appl. No. 16/532,260, filed Aug. 5, 2019, 2 pages.
Corrected Notice of Allowability dated Apr. 15, 2022, for U.S. Appl. No. 17/239,270, filed Apr. 23, 2021, 2 pages.
Corrected Notice of Allowability dated Oct. 14, 2022, for U.S. Appl. No. 17/033,408, filed Sep. 25, 2020, 2 pages.
Defendant Ivantis, Inc.'s Corrected Initial Invalidity Contentions, In the United States District Court for the District of Delaware, C.A. No. 21-1317-VAC-SRF, 53 total pages.
Drusedau, M.U.H. et al. (2000). “Viscocanalostomy for primary open-angle glaucoma: The gross Pankow experience,” J. Cataract Refract. Surg. 26:1367-1373.
Extended European Search Report dated Feb. 4, 2022, for European Patent Application No. 21 179 625.5, filed on Mar. 31, 2015, 8 pages.
Final Office Action dated Apr. 1, 2021, for U.S. Appl. No. 16/532,260, filed Aug. 5, 2019, 8 pages.
Final Office Action dated Dec. 21, 2021, for U.S. Appl. No. 17/239,270, filed Apr. 23, 2021, 14 pages.
Glaukos iStent (2022). iStent inject® W, 9 total pages.
Guerrero, A.H. et al. (2000). “Complications of glaucoma drainage implant surgery,” Int. Ophthalmol. Clin. 40:149-163.
Johnson, D.H. et al. (2001). “How does nonpenetrating glaucoma surgery work? Aqueous outflow resistance and glaucoma surgery.” J. Glaucoma 10:55-67.
Minckler, D. et al. (2006). “Aqueous shunts for glaucoma (review,” Cochrane Library, 47 total pages.
Non-Final Office Action dated Aug. 10, 2020, for U.S. Appl. No. 14/973,620, filed Dec. 17, 2015, 8 pages.
Non-Final Office Action dated Oct. 1, 2020, for U.S. Appl. No. 16/397,733, filed Apr. 29, 2019, 7 pages.
Non-Final Office Action dated Jul. 15, 2021, for U.S. Appl. No. 17/239,263, filed Apr. 23, 2021, 9 pages.
Non-Final Office Action dated Aug. 26, 2021, for U.S. Appl. No. 17/239,270, filed Apr. 23, 2021, 21 pages.
Non-Final Office Action dated Mar. 4, 2022, for U.S. Appl. No. 17/553,671, filed Dec. 16, 2021, 9 pages.
Non-Final Office Action dated Mar. 10, 2022, for U.S. Appl. No. 17/553,408, filed Dec. 16, 2021, 18 pages.
Non-Final Office Action dated Apr. 26, 2022, for U.S. Appl. No. 16/413,466, filed May 15, 2019, 8 pages.
Non-Final Office Action dated Aug. 4, 2022, for U.S. Appl. No. 17/827,494, filed May 27, 2022, 20 pages.
Non-Final Office Action dated Aug. 24, 2022, for U.S. Appl. No. 17/827,485, filed May 27, 2022, 25 pages.
Notice of Allowance dated Aug. 20, 2020, for U.S. Appl. No. 16/189,882, filed Nov. 13, 2018, 8 pages.
Notice of Allowance dated Sep. 16, 2020, for U.S. Appl. No. 15/854,126, filed Dec. 26, 2017, 9 pages.
Notice of Allowance dated Aug. 2, 2021, for U.S. Appl. No. 17/239,263, filed Apr. 23, 2021, 5 pages.
Notice of Allowance dated Sep. 17, 2021, for U.S. Appl. No. 16/532,260, filed Aug. 5, 2019, 9 pages.
Notice of Allowance dated Mar. 15, 2022, for U.S. Appl. No. 17/239,270, filed Apr. 23, 2021, 8 pages.
Notice of Allowance dated May 31, 2022, for U.S. Appl. No. 17/553,671, filed Dec. 16, 2021, 7 pages.
Notice of Allowance dated Jun. 8, 2022, for U.S. Appl. No. 16/413,466, filed May 15, 2019, 5 pages.
Notice of Allowance dated Jun. 28, 2022, for U.S. Appl. No. 17/553,408, filed Dec. 16, 2021, 9 pages.
Notice of Allowance dated Jul. 8, 2022, for U.S. Appl. No. 17/033,408, filed Sep. 25, 2020, 12 pages.
Samuelson, T.W. (2011). “Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract,” Ophthalmol. 118:459-467.
Schwartz, K.S. et al. (2006). “Glaucoma drainage implants: A critical comparison of types,” Curr. Opin. Ophthalmol. 17:181-189.
Sidoti, P.A. et al. (1994). “Glaucoma drainage implants,” Curr. Opin. Ophthalmol. 11:85-98.
Stefansson, J. (1925). “American journal of ophthalmology,” vol. 8, pp. 681-693.
Yablonski, M.E. (2005). “Trabeculectomy with internal tube shunt—A novel glaucoma surgery,” J. Glaucoma 14:91-97.
Zhou, J. et al. (2006). “Trabecular bypass—Effect of Schlemm canal and collector channel dilation,” J. Glaucoma 15:446-455.
Ahn, W. et al. (2002). “The “Gauge” System for the Medical Use,” Anesth. Analg. 95:1125, with Table 1.
Aragona, P. et al. (2002). “Long Term Treatment with Sodium Hyaluronate-Containing Artificial Tears Reduces Ocular Surface Damage in Patients with Dry Eye,” Br. J. Ophthalmol. 86:181-184.
Balazs, E.A. et al. (1972). “Hyaluronic Acid and Replacement of Vitreous and Aqueous Humor,” Modern Problems in Ophthalmology 10:3-21.
Jacob, J.S. (1985). “Corneal thickness changes following cataract surgery: effect of lens implantation and sodium hyaluronate,” British Journal of Ophthalmology 69:567-571.
Myers, T.D. et al. (1999). “Comparison of the Effects of Viscoelastic Agents on Clinical Properties of the Unfolder Lens Injection System,” Journal of Cataract and Refractive Surgery 25:953-958.
Nesterov, A.P. (1970). “Role of Blockage of Schlemm's Canal in Pathogenesis of Primary Open-Angle Glaucoma,” Am. J. Ophthalmol. 70:691-696.
Razeghinejad, M.R. et al. (2011). “A History of the Surgical Management of Glaucoma,” Optom. Vis. Sci. 88:E39-E47.
Summary of Safety and Effectiveness Data, STAARVISCTM (sodium hyaluronate) Premarket Approval Application (PMA) No. P000046, Apr. 18, 2001, 11 total pages.
Stegmann, R. et al. (1999). “Viscocanalostomy for Open-Angle Glaucoma in Black African Patients,” Journal of Cataract & Refractive Surgery 25:316-322.
Stegmann, R. (2002). Robert Stegmann, MD: taking on the challenges of ocular trauma and disease, Ocular Surgery News, located at https://www.healio.com/news/ophthalmology/20120331/robert-stegmann-md-taking-on-the-challenges-of-ocular-trauma-and-disease, 4 total pages.
Wild, G.J. et al. (2001). “Dilation of Schlemm's Canal in Viscocanalostomy: Comparison of 2 Viscoelastic Substances,” Journal of Cataract and Refractive Surgery 27:1294-1297.
Alcon-Ivantis Claim Construction Hearing Powerpoint Slides (Feb. 9, 2023). Sight Sciences, Inc., v. Ivantis, Inc., Alcon Research LLC, Alcon Vision, LLC, and Alcon Inc., No. 21-1317-GBW-SRF, 86 total pages.
Final Office Action dated Dec. 27, 2022, for U.S. Appl. No. 17/827,485, filed May 27, 2022, 30 pages.
International Search Report dated Nov. 2, 2022, for PCT Application No. PCT/US2022/031457, filed on May 27, 2022, 4 pages.
Joint Claim Construction Brief (Jan. 26, 2023). Sight Sciences, Inc. v. Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., C.A. No. 21-1317-GBW-SRF, filed on Jan. 26, 2023, In the United States District Court for the District of Delaware, 91 total pages.
Notice of Allowance dated Nov. 23, 2022, for U.S. Appl. No. 17/827,494, filed May 27, 2022, 8 pages.
Petition for Inter Partes Review Under 37 C.F.R. § 42.101 (Sep. 12, 2022). Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., Petitioners v. Sight Sciences, Inc., Patent Owner, filed on Sep. 12, 2022, IPR2022-01529, U.S. Pat. No. 9,370,443, United States Patent and Trademark Office Before the Patent Trial and Appeal Board, 98 total pages.
Petition for Inter Partes Review Under 37 C.F.R. § 42.101 (Sep. 12, 2022). Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., Petitioners v. Sight Sciences, Inc., Patent Owner, filed on Sep. 12, 2022, IPR2022-01530, U.S. Pat. No. 10,314,742, United States Patent and Trademark Office Before the Patent Trial and Appeal Board, 102 total pages.
Petition for Inter Partes Review Under 37 C.F.R. § 42.101 (Sep. 14, 2022). Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., Petitioners v. Sight Sciences, Inc., Patent Owner, filed on Sep. 14, 2022, IPR2022-01533, U.S. Pat. No. 8,287,482, United States Patent and Trademark Office Before the Patent Trial and Appeal Board, 107 total pages.
Petition for Inter Partes Review Under 37 C.F.R. § 42.101 (Sep. 16, 2022). Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., Petitioners v. Sight Sciences, Inc., Patent Owner, filed on Sep. 16, 2022, IPR2022-01540, U.S. Pat. No. 9,486,361, United States Patent and Trademark Office Before the Patent Trial and Appeal Board, 100 total pages.
Second Amended Complaint (Aug. 1, 2022). Sight Sciences, Inc. v. Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., C.A. No. 21-1317-VAC-SRF, filed on Aug. 1, 2022, In the United States District Court for the District of Delaware, 49 total pages.
Second Amended Complaint—Exhibits A-P (Aug. 1, 2022). Sight Sciences, Inc. v. Ivantis, Inc. Alcon Research LLC, Alcon Vision, LLC and Alcon Inc., C.A. No. 1-21-1317-GBW-SRF, filed on Aug. 1, 2022, In the United States District Court for the District of Delaware, 345 total pages.
Sight Sciences, Inc., v. Ivantis, Inc., Alcon Research LLC, Alcon Vision, LLC, and Alcon Inc., No. 21- 1317-GBW-SRF (Feb. 9, 2023). Plaintiff's Markman Hearing Presentation, 130 total pages.
Written Opinion of the International Searching Authority dated Nov. 2, 2022, for PCT Application No. PCT/US2022/031457, filed on May 27, 2022, 11 pages.
Abu-Hassan, D.W. et al. (2014). “The trabecular meshwork: A basic review of form and function,” J. Ocul. Biol. 2(1), 22 total pages.
Bonsignore, C. (2003). “A decade of evolution in stent design,” SMST-2003, Proceedings of the International Conference on Shape and Memory and Superelastic Technologies, pp. 519-528, 13 total pages.
Brubaker, R.F. (2004). “Goldmann's equation and clinical measures of aqueous dynamics,” Experimental Eye Research 78:633-637.
Brunette, D.M. et al. (2001). “Chapter 8: Mechanical, thermal, chemical and electrochemical surface treatment of titanium,” in Titanium in Medicine: Material science, engineering, biological responses and medical applications, Springer, pp. 232-266.
Corrected Notice of Allowability dated Mar. 3, 2023, for U.S. Appl. No. 17/827,494, filed May 27, 2022, 5 pages.
Defendant Ivantis, Inc.'s Second Supplemental Initial Invalidity Contentions. In the United States District Court for the District of Delaware, Case No. C.A. No. 21-1317-GBW-SRF, filed on Jun. 29, 2023, Sight Sciences, Inc., Plaintiff, with Exhibit Nos. 328 (A17, A18, A19, A20), 361 (A17, A18, A19, A20), 443 (A14, A15, A16, A17), 482 (A14, A15, A16, A17) and 742 (A14, A15, A16, A17, A18), 1,893 total pages.
Dietlein, T.S. et al. (2008). “Combined cataract-glaucoma surgery using the intracanalicular Eyepass glaucoma implant: first clinical results of a prospective pilot study,” J. Cataract Refract Surg. 34:247-252.
Duerig, T. et al. (1999). “An overview of nitinol medical applications,” Materials Science and Engineering A273-275:149-160.
Food and Drug Administration (Apr. 1, 2004). “Title 21—Food and Drugs Chapter I—Food and Drug Administration Department of Health and Human Services Subchapter H—Medical Devices,” 2 total pages.
Glaukos Corporation iStent® Trabecular Micro-Bypass Stent (2021). Directions for Use/Package Insert, 23 total pages.
Healio (May 4, 2004). “EyePass glaucoma device shows promise,” Ocular Surgery News, located at https://www.healio.com/news/ophthalmology/20120331/eyepass-glaucoma-device-shows-promise, 2 total pages.
Healio (Sep. 15, 2002). “Robert Stegmann, MD: taking on the challenges of ocular trauma and disease,” Ocular Surgery News 20th Anniversary, 5 total pages.
Hill, R. (Nov./Dec. 2012). “Sidebar: Inventor's Perspective,” located at https://glaucomatoday.com/articles/2012-nov-dec/sidebar-inventors-perspective, 3 total pages.
Hsu, S.W. et al. (May 2006). “In Vitro Studies of the Neuroform Microstent Using Transparent Human Intracranial Arteries,” AJNR Am. J. Neuroradiol. 27:1135-1139.
Khng, C. et al. (2008). “Evaluation of the relationship between corneal diameter and lens diameter,” J. Cataract Refract. Surg. 34:475-479.
Llobet, A et al. (2003). “Understanding Trabecular Meshwork Physiology: A Key to the Control of Intraocular Pressure?” News Physiol. Sci. 18:205-209.
Mishra, P et al. (Nov. 17, 2014). “Glaucoma drainage device: A review,” Journal of Evolution and Medical and Dental Sciences, vol. 3, Issue 62, pp. 13744-13758.
Nitinol Product Information (2003). Memry Materials, 5 total pages.
Non-Final Office Action dated Mar. 16, 2023, for U.S. Appl. No. 17/397,817, filed Aug. 9, 2021, 8 pages.
Non-Final Office Action dated Jun. 23, 2023, for U.S. Appl. No. 18/130,353, filed Apr. 3, 2023, 15 pages.
Non-Final Office Action dated Jun. 26, 2023, for U.S. Appl. No. 18/130,354, filed Apr. 3, 2023, 16 pages.
Notice of Allowance dated Apr. 27, 2023, for U.S. Appl. No. 17/990,589, filed Nov. 18, 2022, 12 pages.
Notice of Allowance dated May 4, 2023, for U.S. Appl. No. 17/827,485, filed May 27, 2022, 12 pages.
Opening Expert Report of Joseph A. Izatt, Ph.D. In the United States District Court for the District of Delaware, Case No. C.A. No. 21-1317-GBW-SRF, filed on Jul. 11, 2023, Sight Sciences, Inc., Plaintiff, with Exhibit Nos. A and B, 194 total pages.
Opening Expert Report of Angelo P. Tanna, M.D. In the United States District Court for the District of Delaware, Case No. C.A. No. 21-1317-GBW-SRF, filed on Jul. 13, 2023, Sight Sciences, Inc., Plaintiff, with Exhibit Nos. 1 through 22, 936 total pages.
Pride, G.L. et al. (2004). “Stent-coil treatment of a distal internal carotid artery dissecting pseudoaneurysm on a redundant loop by use of a flexible, dedicated nitinol intracranial stent,” AJNR Am. J. Neuroradiol. 25:333-337.
Prielipp, R.C. et al. (2007). “Stents, Stents, Everywhere—Now even in the BRAIN,” apsf Newsletter, 8 total pages.
Schlemm's Canal Position Inside the Eye (IMAGE), EurekAlert! 2023, located at https://www.eurekalert.org/multimedia/757562, 2 total pages.
Sherwood, M. et al. (Mar. 1, 2006). “Rethinking glaucoma surgery: Aqueous within the eyewall,” David E.I. Pyott Glaucoma Education Center, located at https://www.aao.org/education/current-insight/rethinking-glaucoma-surgery-aqueous-within-eyewall, 5 total pages.
Shrestha, S. et al. (2020). “Coronary artery stents: From the beginning to the present,” Consultant 60:e1, 13 total pages.
Stoeckel, D. et al. (2002). “A survey of stent designs,” Min. Invas. Ther. & Allied Technol. 11:137-147.
Usui, T. et al. (Aug. 2011). “Identification of Schlemm's canal and its surrounding tissues by anterior segment fourier domain optical coherence tomography,” Invest. Ophthalmol. Vis. Sci. 52:6934-6939.
Weinreb, R.N. et al. (2004). “Primary open-angle glaucoma,” Lancet 363:1711-1720.
Wittman, B. et al. (2017). “Eyepass Glaucoma Implant in Open-Angle Glaucoma After Failed Conventional Medical Therapy: Clinical Results of a 5-Year-Follow-up,” J. Glaucoma 26:328-334.
Related Publications (1)
Number Date Country
20200121503 A1 Apr 2020 US
Continuations (4)
Number Date Country
Parent 15340911 Nov 2016 US
Child 16526832 US
Parent 13445816 Apr 2012 US
Child 15340911 US
Parent 12695053 Jan 2010 US
Child 13445816 US
Parent 11475523 Jun 2006 US
Child 12695053 US